MedTrace Logo

A Study To Characterize The Pharmacokinetics Of Oxycodone In Healthy Volunteers

NCT01552863 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2015-08-31

No results posted yet for this study

Summary

This is an open-label (both the physician and healthy volunteer know which medication will be administered), single-dose, 6- dosing period study to characterize the pharmacokinetics of oxycodone (process by which oxycodone is absorbed, distributed, metabolized, and eliminated by the body). This study will consist of three parts that will take place over approximately 90 days. Part 1 of the study has 4 dosing periods, while Parts 2 and 3 have one dosing period each.

Conditions

Interventions

DRUG

Oxycodone

One capsule of 40 mg PF-00345439 Formulation A, single dose

DRUG

Oxycodone

One capsule of 40 mg PF-00345439 Formulation E, single dose

DRUG

Oxycodone

One capsule of 40 mg PF-00345439 Formulation F, single dose

DRUG

Oxycodone

One capsule of 40 mg PF-00345439 Formulation G, single dose

DRUG

Oxycodone

One capsule of 5 mg PF-00345439 Formulation TBD, single dose

DRUG

Oxycodone

One capsule of 40 mg PF-00345439 Formulation H, single dose

Sponsors & Collaborators

  • Pain Therapeutics

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01552863 on ClinicalTrials.gov